Invitae Stock

Invitae EBITDA Growth YoY

Delisted·Aug 7, 2024

The Year-over-Year EBITDA Growth of Invitae (NVTAQ) as of Aug 10, 2026 is 124.90 %. In the previous year, Year-over-Year EBITDA Growth was -6.52 % — a change of -2,015.05% (higher).

EBITDA Growth YoY

124.90 %

YoY

-2,015.05%

Last updated:

Year-over-Year EBITDA Growth of Invitae is 2026 124.90 % . Year-over-Year EBITDA Growth of Invitae was 2025 -6.52 % . It decreases by -2,015.05% higher compared to the previous year.
Access this data via the Eulerpool API

Invitae Stock analysis

What does Invitae do? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invitae stock

Year-over-Year EBITDA Growth of Invitae is 124.90 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Invitae since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Invitae historically and in real time.

Access this data via the Eulerpool API

Growth — Invitae

All Key Metrics — Invitae